Kristine Cannon

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

Thomas Louie, Kristine Cannon, Brendan Byrne et al. · Clinical Infectious Diseases · 2012 · 305 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection

Kristine Cannon, Brendan Byrne, Jennifer Happe et al. · Journal of Antimicrobial Chemotherapy · 2017 · 34 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +10

Timing of treatment initiation for mild gestational diabetes mellitus and perinatal outcomes

Anna Palatnik, Lisa Mele, Mark B. Landon et al. · American Journal of Obstetrics and Gynecology · 2015 · 31 citations

Medicine, Endocrinology, Obstetrics +15

Differences of the Fecal Microflora With Clostridium difficile Therapies

Thomas Louie, Brendan Byrne, J.C. Herbert Emery et al. · Clinical Infectious Diseases · 2015 · 26 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth

Martha L. Bustos, Steve N. Caritis, Kathleen A. Jablonski et al. · American Journal of Obstetrics and Gynecology · 2017 · 15 citations · Full text

Medicine, Endocrinology, Obstetrics +17